Severe COVID-19
Indication: Hospitalized patients with Severe COVID-19
Title: Phase 2 Randomized Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor in Patients with Severe COVID-19
Drug: Selinexor
This study has been discontinued as of August 2020
Please visit clinicaltrials.gov for more information about this study
Phase I | Phase II | Phase III |
---|---|---|
Phase I | Phase II | Phase III |